publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
untreat
unresect
wildtyp
kra
exon
metastat
colorect
cancer
j
clin
oncol
karthau
schwartzberg
l
rivera
f
et
al
updat
overal
surviv
os
analysi
novel
predict
krasnra
mutat
beyond
kra
exon
peak
phase
studi
plu
panitumumab
pmab
bevacizumab
bev
metastat
colorect
cancer
mcrc
eur
j
cancer
ciardiello
f
lenz
hj
kohn
ch
et
al
treatment
outcom
accord
tumor
ra
mutat
statu
crystal
studi
patient
metastat
colorect
cancer
mcrc
random
folfiri
withwithout
cetuximab
j
clin
oncol
abstr
amado
rg
wolf
peeter
et
al
wildtyp
kra
requir
panitumumab
efficaci
patient
metastat
colorect
cancer
j
clin
oncol
jonker
dj
ocallaghan
cj
karapeti
cs
et
al
cetuximab
treatment
colorect
cancer
n
engl
j
med
venook
ap
niedzwiecki
lenz
hj
et
al
calgbswog
phase
iii
trial
folfiri
bevacizumab
bv
cetuximab
cet
patient
pt
kra
wildtyp
patient
profound
neutropenia
last
day
develop
lung
infiltr
frequent
respond
broadspectrum
antibacteri
therapi
caus
pathogen
remain
undetect
major
case
aspergillu
spp
pneumocysti
jirovecii
multiresist
gramneg
pathogen
mycobacteria
respiratori
virus
may
involv
atrisk
patient
receiv
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
filament
fungal
pathogen
appear
predomin
yet
commonli
proven
time
treatment
initi
manuscript
refer
patient
undergo
allogen
hematopoiet
stem
cell
transplant
patient
subject
separ
agiho
guidelin
pathogen
isol
blood
cultur
bronchoalveolar
lavag
bal
respiratori
secret
alway
relev
etiolog
pulmonari
infiltr
therefor
interpret
critic
laboratori
test
detect
aspergillu
galactomannan
dna
blood
bal
tissu
sampl
may
facilit
diagnosi
howev
polymeras
chain
reaction
assay
yet
standard
valid
apart
infecti
agent
pulmonari
sideeffect
cytotox
drug
radiotherapi
pulmonari
involv
underli
malign
includ
differenti
diagnosi
eventu
clarifi
invas
diagnost
procedur
preemptiv
treatment
moldact
system
antifung
agent
improv
clinic
outcom
microorgan
prefer
treat
microbiolog
document
highdos
tmpsmx
first
choic
treatment
pneumocysti
pneumonia
cytomegaloviru
pneumonia
treat
primarili
ganciclovir
foscarnet
patient
consider
number
patient
clinic
outcom
may
favor
despit
respiratori
failur
intens
care
unrestrictedli
provid
patient
whose
prognosi
desper
due
reason
respect
critic
prognosi
lung
infiltr
li
febril
neutropen
patient
diagnost
procedur
major
import
caus
substanti
delay
start
adequ
antimicrobi
therapi
imag
convent
chest
radiograph
show
abnorm
febril
neutropen
patient
without
clinic
find
indic
lower
respiratori
tract
infect
undetermin
mani
patient
would
abnorm
comput
tomographi
ct
scan
random
headtohead
comparison
publish
far
patient
persist
febril
h
broadspectrum
antibacteri
therapi
chest
radiograph
abnorm
wherea
highresolut
ct
scan
time
reveal
patholog
find
patient
earli
detect
lesion
indic
invas
mold
infect
pneumocysti
pneumonia
pcp
utmost
import
facilit
target
bronchoscopi
bronchoalveolar
lavag
bal
prompt
institut
preemptiv
antimicrobi
treatment
enabl
better
surviv
patient
ct
find
consolid
halo
sign
aircresc
sign
obtain
highresolut
multislic
ct
scan
may
import
sign
filament
fungal
diseas
halo
sign
describ
typic
neutropen
patient
ct
find
indic
ipa
compar
neutropen
nonneutropen
patient
revers
halo
sign
show
focal
round
area
groundglass
opac
surround
crescent
complet
ring
consolid
report
rel
specif
fungal
pneumonia
due
zygomycetesmucoral
howev
may
repres
broad
spectrum
differenti
diagnos
includ
tuberculosi
sarcoidosi
cryptogen
organ
pneumonia
beyond
earli
identif
li
ct
find
may
allow
distinguish
fungal
nonfung
li
diffus
bilater
perihilar
infiltr
patchi
area
groundglass
attenu
peripher
spare
cyst
septal
thicken
consolid
centrilobular
nodul
may
indic
pcp
nodular
cavitari
lesion
suggest
invas
filament
fungal
infect
howev
differenti
diagnos
includ
pneumonia
due
microorgan
includ
mycobacteria
may
relev
region
high
preval
nocardia
pneumocysti
pseudomona
aeruginosa
p
aeruginosa
well
lung
involv
underli
malign
comparison
previou
ct
scan
individu
patient
essenti
combin
ct
scan
angiographi
found
increas
diagnost
specif
patient
pulmonari
mold
infect
howev
labor
intens
method
yet
becom
wide
appli
therefor
includ
current
clinic
practic
guidelin
select
patient
pulmonari
ct
scan
want
feasibl
magnet
reson
tomographi
mri
valid
altern
bii
yet
consensu
definit
invas
fungal
diseas
includ
thorac
mri
find
select
patient
unexplain
fever
neutropenia
f
emiss
tomographi
combin
comput
tomographi
petct
may
help
particularli
rule
undetect
infect
followup
thorac
ct
scan
gener
order
day
start
treatment
aii
patient
ipa
may
show
increas
volum
pulmonari
infiltr
first
week
despit
effect
antifung
therapi
find
alon
give
reason
assess
treatment
cours
refractori
aii
reduct
halo
develop
aircresc
sign
howev
typic
indic
favor
respons
major
febril
neutropen
patient
li
prove
microbiolog
find
avail
therapeut
manag
base
upon
clinic
imag
find
see
microbiolog
document
case
pathogen
typic
isol
blood
cultur
bronchial
secret
bal
fluid
often
mean
challeng
assess
diagnost
relev
cultur
result
unselect
bronchial
sampl
patient
grow
colon
contamin
microorgan
etiolog
signific
blood
cultur
may
show
isol
etiolog
relat
pneumonia
time
autopsi
show
invas
fungal
infect
detect
ant
mortem
therefor
contrast
major
microbiolog
find
isol
aspergillu
spp
filament
fungi
upper
respiratori
tract
specimen
sever
immunocompromis
patient
typic
indic
respiratori
tract
mycosi
diagnost
yield
outcom
clinic
manag
critic
ill
febril
cancer
patient
sever
pulmonari
infiltr
improv
invas
diagnost
procedur
includ
bal
detect
rate
potenti
pathogen
bal
sampl
describ
even
higher
depend
risk
profil
patient
includ
retrospect
analysi
microbiolog
find
bal
sampl
cancer
patient
li
show
bacteria
cytomegaloviru
cmv
pneumocysti
jirovecii
p
jirovecii
aspergillu
spp
anoth
report
bronchoscopi
febril
patient
hematolog
malign
describ
pathogen
possibl
etiolog
signific
sampl
sampl
grew
bacteria
show
fungi
bacteria
sampl
aspergillu
spp
sampl
candida
speci
sampl
aspergillu
candida
spp
mani
li
sever
immunocompromis
patient
may
also
polymicrobi
etiolog
mold
predominantli
aspergillu
spp
plu
bacteria
multipl
fungal
speci
sampl
although
etiolog
relev
bal
find
may
question
mani
case
result
trigger
chang
antimicrobi
treatment
patient
diagnost
gold
standard
lack
number
falseposit
falseneg
find
unknown
rate
success
failur
pathogendirect
antimicrobi
treatment
therefor
remain
undetermin
propos
assess
etiolog
signific
microbiolog
find
febril
neutropen
patient
li
given
antimicrobi
treatment
patient
document
pathogen
section
proven
diagnosi
ipa
cultur
isol
fungi
histolog
proof
lung
tissu
regard
diagnost
gold
standard
qualiti
standard
diagnost
procedur
avail
patient
undergo
biopsi
highli
select
histolog
proof
alon
accuraci
aspergillu
around
histolog
alway
combin
fungal
cultur
cultur
independ
method
eg
nucleic
acid
base
polymeras
chain
reaction
pcr
may
help
especi
patient
alreadi
receiv
antifung
treatment
difficulttocultur
pathogen
mucoral
transbronchi
biopsi
recommend
sever
thrombocytopen
patient
lung
infiltr
openlung
biopsi
olb
minithoracotomi
videoassist
thoracoscop
surgeri
may
safe
carri
patient
treatmentrefractori
li
clearedup
diagnost
approach
primarili
order
rule
noninfecti
origin
olb
rel
safe
procedur
complic
rate
includ
risk
hemorrhag
even
thrombocytopen
patient
histolog
infect
malign
nonspecif
inflamm
detect
major
patient
notabl
find
olb
bal
obtain
simultan
may
show
differ
microbiolog
result
ctguid
percutan
sidecut
core
needl
biopsi
may
provid
inform
result
case
allow
speci
identif
use
molecular
method
tissu
workup
percutan
biopsi
requir
platelet
count
plu
suffici
coagul
indic
eg
aptt
ratio
limit
patient
without
obviou
risk
respiratori
failur
case
complic
pneumothorax
yet
report
prospect
studi
compar
differ
method
invas
approach
identifi
caus
li
febril
neutropen
patient
nonculturebas
diagnost
method
cytomegaloviru
respiratori
virus
patient
profound
cellular
immunosuppress
respiratori
virus
may
caus
li
diagnost
program
use
workup
bal
oronasopharyng
swab
includ
cmv
well
influenza
parainfluenza
respiratori
syncyti
viru
coronaviru
rhinoviru
human
metapneumoviru
febril
neutropen
patient
li
cmv
pcr
appli
bal
sampl
high
neg
low
posit
predict
valu
posit
rapid
cultur
immedi
earli
antigen
direct
fluoresc
antibodi
test
dna
hybrid
cytolog
bal
cultur
requir
confirm
diagnosi
cmv
pneumonia
pneumocysti
jirovecii
besid
microscop
identif
classic
refer
method
detect
p
jirovecii
pcr
introduc
earli
detect
pathogen
high
sensit
essenti
distinguish
infect
colon
may
present
individu
without
sign
symptom
pcp
metaanalysi
show
high
sensit
specif
neg
pneumocystispcr
bal
sampl
time
diagnosi
allow
put
asid
antipneumocysti
therapi
recent
develop
quantit
pcr
assay
appear
increas
specif
report
nonhiv
patient
proven
pcp
show
posit
predict
valu
pathogen
per
ml
detect
bal
sampl
determin
serum
may
add
differenti
diagnosi
neg
result
test
make
pcp
highli
unlik
filament
fungi
numer
method
develop
detect
fungal
cell
antigen
aspergillu
galactomannan
gm
nuclear
amplif
assay
identifi
fungal
dna
earli
noninvas
detect
filament
fungi
febril
neutropen
patient
li
undetermin
etiolog
posit
ie
od
gm
test
blood
bal
sampl
cutoff
might
appropri
accept
signific
find
indic
probabl
invas
fungal
infect
sever
immunocompromis
patient
question
aspergillu
gm
blood
becom
posit
earlier
chest
ct
scan
notabl
gm
test
may
give
falseposit
result
patient
treat
semisynthet
antibiot
amoxicillinclavulan
piperacillintazobactam
carbapenem
ceftriaxon
cefepim
well
given
enter
nutrit
fungal
infect
fusariosi
bal
sampl
obtain
use
specif
lavag
solut
falseposit
aspergillu
antigenemia
may
also
due
blood
product
condit
fluid
signific
declin
galactomannan
aspergillu
antigen
signal
describ
storag
serum
sampl
contrast
bal
sampl
time
take
blood
sampl
test
minim
detail
antigen
test
fungal
infect
includ
aspergillosi
review
separ
evidencebas
guidelin
group
studi
panfung
aspergillusspecif
pcr
assay
indic
use
techniqu
bal
sampl
seem
superior
compar
blood
sampl
particularli
patient
undergo
system
antifung
therapi
lung
biopsi
specimen
pcr
ad
histopatholog
cultur
may
improv
specif
pathogen
sinc
wide
accept
intern
standard
assay
avail
yet
blood
bal
sampl
pcr
result
becom
part
definit
criteria
invas
fungal
infect
pcr
presum
becom
part
diagnost
program
li
includ
thorac
ct
scan
serolog
convent
microbiolog
blood
bal
sampl
combin
aspergillu
pcr
gm
bal
sampl
enhanc
diagnost
sinc
posit
result
gm
pcr
make
pulmonari
aspergillosi
highli
like
confirm
recent
metaanalys
previou
exposur
antifung
therapi
may
reduc
sensit
galactomannan
well
quantit
pcr
assay
legionella
pneumophila
serogroup
antigen
nosocomi
outbreak
legionellosi
among
cancer
leukemia
patient
becom
rare
singlecent
report
indic
differenti
diagnosi
ignor
test
legionella
pneumophila
serogroup
urin
help
detect
diagnosi
rapidli
control
clinic
studi
use
routin
test
antigen
among
febril
neutropen
patient
lung
infiltr
avail
biomark
nonspecif
proinflammatori
laboratori
paramet
like
creactiv
protein
tumor
necrosi
procalcitonin
plasma
level
frequent
use
assess
sever
infect
respons
antimicrobi
therapi
febril
neutropen
patient
li
predict
valu
paramet
investig
prospect
studi
yet
clinic
practic
repeat
measur
paramet
typic
parallel
clinic
observ
use
therapeut
decis
context
clinic
imag
find
persist
fever
progress
newli
emerg
li
rise
proinflammatori
paramet
typic
indic
need
chang
antimicrobi
treatment
regimen
algorithm
clinic
manag
febril
neutropen
patient
li
propos
figur
synops
recommend
diagnost
measur
given
tabl
recommend
antimicrobi
treatment
clinic
manag
summar
tabl
patient
acut
myeloid
leukemia
myelodysplast
syndrom
undergo
aggress
myelosuppress
chemotherapi
expect
sever
neutropenia
last
day
serial
monitor
aspergillu
galactomannan
blood
sampl
recommend
bii
place
yet
clearli
defin
pcr
studi
frame
clinic
trial
serial
panfung
pcr
monitor
patient
acut
leukemia
undergo
intens
myelosuppress
persist
fever
andor
sign
andor
symptom
lower
respiratori
tract
infect
review
chemotherapi
fail
identifi
patient
particularli
high
risk
develop
invas
fungal
diseas
importantli
diagnost
procedur
aim
obtain
microbiolog
result
confirm
help
modifi
antimicrobi
therapi
initi
without
await
result
diagnost
procedur
aii
patient
fever
unknown
origin
respond
appropri
firstlin
therapi
h
undergo
thorough
physic
reexamin
imag
tabl
microbiolog
diagnost
includ
nativ
thorac
ct
scan
ct
scan
paranas
sinus
symptom
sign
sinus
present
aii
highresolut
multislic
thorac
ct
scan
must
avail
maximum
h
clinic
indic
establish
aii
li
document
noninvas
diagnost
test
repeat
bronchoscopi
bal
tabl
arrang
within
maximum
h
biii
bal
sampl
must
sent
immedi
microbiolog
laboratori
workup
start
within
h
sampl
aiii
recommend
microbiolog
procedur
list
tabl
standard
procedur
bronchoscopi
bal
recommend
aii
invas
procedur
openlung
percutan
core
needl
biopsi
consid
patient
consid
dismal
prognosi
febril
neutropen
patient
li
treat
promptli
appropri
antimicrobi
regimen
recommend
start
therapi
basi
clinic
imag
andor
laboratori
find
indic
particular
infect
patient
risk
without
proof
infect
type
underli
malign
immunosuppress
instrument
impact
select
antimicrobi
agent
suitabl
system
therapi
patient
without
conclus
microbiolog
find
tabl
lack
respons
antimicrobi
treatment
reassess
includ
thorac
ct
scan
eventu
also
bronchoscopi
bal
arrang
day
aii
patient
sever
neutropenia
due
chemotherapi
acut
leukemia
aggress
hematolog
malign
subgroup
febril
neutropen
patient
li
treat
broadspectrum
antipseudomon
activ
use
empir
treatment
fever
unknown
origin
aii
streptococci
includ
cephalosporinresist
strain
must
includ
antimicrobi
spectrum
bii
addit
patient
li
typic
pcp
lobar
bacteri
pneumonia
receiv
moldact
system
antifung
therapi
voriconazol
liposom
amphotericin
b
aii
highrisk
subgroup
patient
signific
benefit
prompt
compar
delay
moldact
antifung
therapi
shown
patient
invas
aspergillosi
treat
voriconazol
liposom
amphotericin
b
superior
respons
surviv
rate
treat
earli
versu
later
cours
diseas
aii
patient
pretreat
voriconazol
posaconazol
system
antifung
prophylaxi
breakthrough
filament
fungal
pneumonia
suspect
measur
antifung
drug
level
invas
diagnost
procedur
taken
consider
biii
treatment
switch
liposom
amphotericin
b
ciii
particularli
patient
mucormycosi
zygomycosi
suspect
liposom
amphotericin
b
recommend
aii
posit
quantit
p
jirovecii
pcr
copiesml
convers
neg
blood
sampl
make
pneumocysti
pneumonia
highli
unlik
follow
find
repres
pathogen
caus
lung
infiltr
isol
enterococci
blood
cultur
swab
sputum
bal
coagulaseneg
staphylococci
corynebacterium
spp
patient
without
microbiolog
proven
indic
addit
aminoglycosid
recommend
due
lack
benefit
ei
patient
receiv
routin
antipneumocysti
prophylaxi
thorac
ct
scan
suggest
pcp
rapid
otherwis
unexplain
rise
serum
lactat
dehydrogenas
prompt
start
highdos
trimethoprimsulfamethoxazol
tmpsmx
therapi
consid
bronchoscopi
bal
bii
case
pcp
bal
remain
posit
pathogen
sever
day
despit
appropri
antimicrobi
therapi
except
select
patient
also
sever
cellular
immunosuppress
antivir
agent
ganciclovir
recommend
earli
preemptiv
therapi
febril
neutropen
patient
li
eii
gener
glycopeptid
fluoroquinolon
macrolid
antibiot
without
specif
pathogen
document
clinic
signific
sampl
use
well
diii
subgroup
febril
patient
hematolog
malign
individu
patient
undergo
highdos
chemotherapi
autolog
hematopoiet
stemcel
transplant
ahsct
febril
neutropenia
li
unknown
origin
whose
condit
regimen
includ
total
bodi
irradi
treat
alemtuzumab
antithymocyt
globulin
fludarabin
bronchoscopi
bal
check
cmv
diseas
may
consid
biii
posit
rapid
cultur
immedi
earli
antigen
prompt
ganciclovir
treatment
mgkg
everi
h
biii
foscarnet
investig
set
sinc
patient
ahsct
low
risk
fungal
pneumonia
preemptiv
antifung
therapi
given
dii
interpret
microbiolog
find
neutropen
patient
li
difficult
tabl
isol
typic
origin
blood
cultur
bal
sampl
may
repres
nonpathogen
contamin
colon
copathogen
microorgan
caus
separ
infect
etiolog
signific
pathogen
detect
particularli
multidrugresist
bacteria
critic
reapprais
antimicrobi
treatment
avoid
fatal
outcom
due
delay
effect
therapi
recommend
aii
antimicrobi
treatment
complic
bacteri
pneumonia
patient
document
p
aeruginosa
pneumonia
primari
combin
antibacteri
therapi
includ
antipseudomon
plu
prefer
aminoglycosid
aminoglycosid
contraind
ciprofloxacin
recommend
mani
author
howev
metaanalys
unequivoc
support
recommend
adequ
monotherapi
may
also
appropri
set
bii
antipseudomon
suitabl
treatment
p
aeruginosa
pneumonia
piperacillin
ceftazidim
imipenemcilastatin
meropenem
cefepim
ai
depend
vitro
suscept
pattern
multiresist
gramneg
aerob
esbl
produc
e
coli
enterobact
spp
klebsiella
spp
well
acinetobact
spp
p
aeruginosa
requir
antimicrobi
treatment
select
appropri
accord
pattern
aii
pharmacokinet
aspect
penetr
lung
tissu
possibl
inactiv
surfact
must
alway
includ
select
aii
individu
patient
pneumonia
caus
multiresist
gramneg
pathogen
aerosol
colistin
success
use
part
antimicrobi
strategi
stenotrophomona
maltophilia
maltophilia
rare
caus
pneumonia
frequent
isol
respiratori
secret
repres
select
opportunist
microorgan
broadspectrum
antibacteri
treatment
individu
patient
tigecyclinebas
treatment
may
appropri
altern
cii
kept
mind
vitro
suscept
may
predict
clinic
efficaci
antimicrobi
agent
maltophilia
infect
pneumonia
caus
methicillinsuscept
staphylococcu
aureu
aureu
treat
oxacillin
flucloxacillin
methicillinresist
aureu
prefer
treat
vancomycin
seriou
renal
insuffici
present
bii
linezolid
possibl
altern
firstlin
treatment
bii
howev
risk
sever
thrombocytopenia
even
pancytopenia
associ
linezolid
must
taken
consider
daptomycin
use
treatment
pneumonia
inactiv
surfact
ei
treatment
cmv
pneumonia
cmv
pneumonia
typic
affect
allogen
stemcel
transplant
recipi
also
relev
patient
treat
lymphocytedeplet
agent
like
alemtuzumab
fludarabin
firstchoic
antivir
treatment
option
foscarnet
ganciclovir
aii
foscarnet
associ
less
myelosuppress
seriou
advers
effect
ganciclovir
hand
revers
nephrotox
one
typic
sideeffect
foscarnet
treatment
document
fungal
pneumonia
detail
recommend
treatment
document
fungal
pneumonia
provid
evidencebas
guidelin
intraven
voriconazol
mgkg
everi
h
day
mgkg
everi
h
thereaft
ai
liposom
amphotericin
b
mg
kgday
aii
recommend
firstlin
choic
treatment
ipa
mucormycosi
zygomycosi
liposom
amphotericin
b
prefer
aii
recommend
dose
mgkgday
aii
patient
worsen
li
ga
exchang
within
first
week
treatment
failur
antifung
therapi
consid
new
li
emerg
control
ct
scan
biii
time
caus
second
infect
immun
reconstitut
syndrom
infiltr
caus
underli
malign
toxic
cancer
treatment
yet
insuffici
durat
antifung
treatment
rule
biii
combin
antifung
firstlin
treatment
patient
invas
mold
infect
controversi
prospect
clinic
studi
compar
voriconazol
alon
combin
voriconazol
anidulafungin
patient
proven
probabl
aspergillosi
yet
publish
detail
treatment
mucormycosi
combin
liposom
amphotericin
b
echinocandin
may
promis
howev
random
studi
subject
conduct
combin
liposom
amphotericin
b
iron
chelat
deferasirox
treatment
mucormycos
shown
inferior
clinic
result
combin
compar
antifung
agent
alon
treatment
document
pneumocysti
pneumonia
pcp
suspect
treatment
tmpsmx
cotrimoxazol
dosag
tmp
mgkg
plu
smx
mgkg
daili
aii
initi
immedi
asserv
repres
sampl
eg
induc
sputum
bal
bii
sinc
treatment
delay
may
enhanc
mortal
mildtomoder
case
oxygen
partial
pressur
po
mmhg
alveolararteri
oxygen
differ
aado
mmhg
oral
therapi
discuss
otherwis
administ
iv
patient
proven
pcp
treatment
tmpsmx
continu
least
week
aii
clinic
improv
develop
within
day
otherwis
second
infect
consid
diagnost
procedur
repeat
individu
patient
persist
pcp
mutat
gene
dihydroptero
synthas
dihydrofol
reductas
may
taken
consider
case
treatment
failur
tmpsmx
intoler
atovaquon
oral
suspens
mg
twice
time
daili
meal
iv
pentamidin
mgkg
daili
clindamycin
mg
four
time
daili
mg
three
time
daili
iv
plu
primaquin
mg
daili
po
may
repres
treatment
altern
clindamycin
primaquin
presum
effect
option
ciii
dehydrogenas
defici
must
exclud
administr
dapson
primaquin
ai
subsequ
patient
given
secondari
prophylaxi
aii
use
oral
tmpsmx
daili
dosag
mg
given
day
per
week
bii
monthli
pentamidin
inhal
dose
mg
bii
patient
respiratori
failur
due
pcp
system
corticosteroid
may
benefici
aid
patient
data
conflict
nonhiv
patient
recent
studi
could
show
clinic
benefit
even
associ
increas
mortal
report
outcom
cancer
patient
requir
intens
care
shown
hospit
surviv
rate
higher
neutropen
patient
respiratori
failur
due
li
may
favor
outcom
appropri
intens
care
includ
mechan
ventil
even
respiratori
failur
due
ipa
surviv
achiev
around
one
third
patient
therefor
justifi
reject
cancer
patient
intens
care
underli
malign
multidisciplinari
care
involv
hematologyoncolog
profession
provid
intens
care
treatment
patient
aii
intens
care
unrestrictedli
provid
patient
respiratori
failur
aii
except
whose
prognosi
desper
due
reason
given
person
direct
order
abstain
